RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
20 oct. 2016 02h30 HE
|
RadioMedix Inc.
Houston, TX, Oct. 20, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston,TX) is excited to announce the completion of the Phase I/II clinical trial of AminoMedix ™ proprietary formulation used...